Botanix Pharmaceuticals plans new study into antimicrobial platform and BTX 1801

Synthetic cannabinoid company Botanix Pharmaceuticals (ASX: BOT) has unveiled the next phase of development for its cannabinoid antimicrobial platform and lead program BTX 1801. Earlier today, Botanix declared it had achieved “significant progress” and is now commencing its first clinical research – a phase 2a study into BTX 1801, targeting the prevention of surgical site infections (SSIs). … Continue reading Botanix Pharmaceuticals plans new study into antimicrobial platform and BTX 1801